MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children. [electronic resource]
Producer: 20170606Description: 990-993 p. digitalISSN:- 1532-1827
- Central Nervous System Neoplasms -- drug therapy
- Child, Preschool
- Female
- GTP Phosphohydrolases -- genetics
- Humans
- Infant
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- Male
- Melanoma -- drug therapy
- Membrane Proteins -- genetics
- Mutation -- genetics
- Prognosis
- Protein Kinase Inhibitors -- therapeutic use
- Pyridones -- therapeutic use
- Pyrimidinones -- therapeutic use
- Skin Neoplasms -- drug therapy
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.